Evaluating entrectinib as a treatment option for non-small cell lung cancer

References

• Sgambato A, Casaluce F, Maione P, et al. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther. 2018;18(1):71–80. .
   PubMed Web of Science ®Google Scholar
• Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res. 2018;24:5807–5814.
   PubMed Web of Science ®Google Scholar
• Pulciani S, Santos E, Lauver AV, et al. Oncogenes in solid human tumours. Nature. 1982;300:539–542.
   PubMed Web of Science ®Google Scholar
• Ardini E, Menichincheri M, Banfi P, et al. Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther. 2016;15:628–639.
   PubMed Web of Science ®Google Scholar
• Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19:1469–1472.
   PubMed Web of Science ®Google Scholar
• Barbacid M, Lamballe F, Pulido D, et al. The trk family of tyrosine protein kinase receptors. Biochim Biophys Acta. 1991;1072:115–127.
   PubMedGoogle Scholar
• Gambella A, Senetta R, Collemi G, et al. NTRK fusions in central nervous system tumors: a rare, but worthy target. Int J Mol Sci. 2020;21:753.
   Web of Science ®Google Scholar
• Liu D, Offin M, Harnicar S, et al. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag. 2018;14:1247–1252.
   PubMed Web of Science ®Google Scholar
• Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731–747.
   PubMed Web of Science ®Google Scholar
• Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1:e000023.
   PubMed Web of Science ®Google Scholar
• Menichincheri M, Ardini E, Magnaghi P, et al. Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor. J Med Chem. 2016;59:3392–3408.
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7:400–409.
   PubMed Web of Science ®Google Scholar
• Rolfo C, Ruiz R, Giovannetti E, et al. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Expert Opin Investig Drugs. 2015;24:1493–1500.
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:261–270.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:271–282.
   PubMed Web of Science ®Google Scholar
• Al-Salama ZT, Keam SJ. Entrectinib: first global approval. Drugs. 2019;79:1477–1483.
   PubMed Web of Science ®Google Scholar
• Rudzinski ER, Lockwood CM, Stohr BA, et al. Pan-Trk immunohistochemistry identifies ntrk rearrangements in pediatric mesenchymal tumors. Am J Surg Pathol. 2018;42:927–935.
   PubMed Web of Science ®Google Scholar
• Märkl B, Hirschbühl K, Dhillon C. NTRK-fusions - A new kid on the block. Pathol Res Pract. 2019;215:152572.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Doebele RC, Farago AF, et al. Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol. 2019;30:ii48-ii49.
   Google Scholar
• Rangaraju S, Farago A, Heym KM, et al. P14.19 preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions. Neuro Oncol. 2017;19:iii106-iii106.
   Web of Science ®Google Scholar
• Lim SM, Kim HR, Lee JS, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35:2613–2618.
   PubMed Web of Science ®Google Scholar
• Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29:e443–445.
   PubMed Web of Science ®Google Scholar
• Park S, Ahn BC, Lim SW, et al. Characteristics and outcome of ROS1-positive non-small cell lung cancer patients in routine clinical practice. J Thorac Oncol. 2018;13:1373–1382.
   PubMed Web of Science ®Google Scholar
• Tan AC, Itchins M, Khasraw M. Brain metastases in lung cancers with emerging targetable fusion drivers. Int J Mol Sci. 2020;21:1416.
   PubMed Web of Science ®Google Scholar
• Patil T, Smith DE, Bunn PA, et al. The Incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13:1717–1726.
   PubMed Web of Science ®Google Scholar
• Siena S, Doebele RC, Shaw AT, et al. Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: integrated analysis from three clinical trials. J clin oncol. 2019;37:3017.
   Web of Science ®Google Scholar
• Lin X, DeAngelis LM. Treatment of Brain Metastases. J Clin Oncol. 2015;33:3475–3484.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon BJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2015;372:683–684.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30:1121–1126.
   PubMed Web of Science ®Google Scholar
• Socinski MA. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. Clin Cancer Res. 2004;10:4210s–4214s.
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378:731–739.
   PubMed Web of Science ®Google Scholar
• Drilon A, Kummar S, Moreno V, et al. Activity of larotrectinib in TRK fusion lung cancer. Ann Oncol. 2019;30:ii48-ii49.
   Web of Science ®Google Scholar
• Drilon AE, DuBois SG, Farago AF, et al. Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors. J clin oncol. 2019;37:2006.
   Web of Science ®Google Scholar
• Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019;30:viii23–viii30.
   Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–838.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK Inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118–1133.
   PubMed Web of Science ®Google Scholar
• Syed YY. Lorlatinib: first global approval. Drugs. 2019;79:93–98.
   PubMed Web of Science ®Google Scholar
• Ku BM, Bae YH, Lee KY, et al. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. Invest New Drugs. 2020;38:360–368.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. JCO Precis Oncol. 2017;2017:10.1200/PO.17.00063.
   Web of Science ®Google Scholar
• Facchinetti F, Friboulet L. Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date. Lung Cancer (Auckl). 2019;10:87–94.
   PubMed Web of Science ®Google Scholar
• Katayama R, Gong B, Togashi N, et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun. 2019;10:3604.
   PubMed Web of Science ®Google Scholar
• Drilon A, Ou SI, Cho BC, et al. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent- front mutations. Cancer Discov. 2018;8:1227–1236.
   PubMed Web of Science ®Google Scholar
• Cho BC, Drilon AE, Doebele RC, et al. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). J clin oncol. 2019;37:9011.
   Web of Science ®Google Scholar
• Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2019;20:1691–1701.
   PubMed Web of Science ®Google Scholar
• Russo M, Misale S, Wei G, et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov. 2016;6:36–44.
   PubMed Web of Science ®Google Scholar
• Drilon A, Li G, Dogan S, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol. 2016;27:920–926.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Larotrectinib: first global approval. Drugs. 2019;79:201–206.
   PubMed Web of Science ®Google Scholar
• Farago A, Kummar S, Moreno V, et al. MA09.07 Activity of Larotrectinib in TRK Fusion Lung Cancer. J Thorac Oncol. 2019;14:S283–S284.
   Web of Science ®Google Scholar
• Jin W. Roles of TrkC signaling in the regulation of tumorigenicity and metastasis of cancer. Cancers (Basel). 2020;12(1):147.
   Web of Science ®Google Scholar
• Hyman D, Kummar S, Farago A, et al. Abstract CT127: phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). Cancer Res. 2019;79:CT127–CT127.
   Web of Science ®Google Scholar